---
document_datetime: 2023-09-21 17:50:57
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vylaer-spiromax-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vylaer-spiromax-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7174615
conversion_datetime: 2025-12-22 20:12:19.088226
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vylaer Spiromax

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A31/0003             | Pursuant to Article 31 of Directive 2001/83/EC, the European Commission initiated a procedure on 27 April 2015 further to concerns over the risk of pneumonia in patients with chronic obstructive pulmonary disease when treated with inhaled corticosteroids containing medicinal products. The PRAC was requested to assess the impact thereof on the benefit-risk balance of inhaled corticosteroids containing medicinal products and to give its | 28/04/2016 product                  | 06/07/2016                                     | SmPC and PL                      | Please refer to the assessment report: Inhaled corticosteroids containing products indicated in the treatment of chronic obstructive pulmonary disease- EMEA/H/A-31/1415 |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Medicinal product no longer authorised

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked.                                                                                                                                                                                                                                                                                            |                    |            |                                  |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|----------------------------------|-----------------------------------|
| IB/0009/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 14/06/2016         | n/a        | longer                           | authorised                        |
| PSUSA/10202 /201510 | Periodic Safety Update EU Single assessment - BUDESONIDE, FORMOTEROL                                                                                                                                                                                                                                                                                                                                                | 13/05/2016         | n/a no     |                                  | PRAC Recommendation - maintenance |
| IB/0008             | B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                | 22/04/2016 product | n/a        |                                  |                                   |
| PSUSA/10202 /201504 | Periodic Safety Update EU Single assessment - BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE                                                                                                                                                                                                                                                                                                                             | 06/11/2015         | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0006/G           | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation Medicinal                                                                                                                                                     | 17/09/2015         | 24/02/2016 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0004/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/07/2015   | n/a           |                        |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------|
| II/0001/G   | procedure This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure product | 26/03/2015   | n/a no longer | authorised             |
| IB/0002/G   | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, Medicinal                                                                                                           | 25/02/2015   | 24/02/2016    | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| ampoules, etc.) in a pack - Change outside the range   |
|--------------------------------------------------------|
| of the currently approved pack sizes                   |

<!-- image -->